ATORVASTATIN and rosuvastatin have again topped the lists of the most commonly prescribed Pharmaceutical Benefits Scheme (PBS) and Repatriation PBS drugs on the basis of both the defined daily dose per 1000 population per day and by prescription counts, according to this year's Australian Prescriber analysis.
Top 10 PBS/RPBS drugs by cost to the tax-payer, excluding rebates, are dominated by biologicals, with hepatitis C drugs and retrovirals also taking some spoils along with new anticoagulant Eliquis (apixaban) from Pfizer.
CLICK HERE for the latest edition of Australian Prescriber.
The above article was sent to subscribers in Pharmacy Daily's issue from 02 Dec 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 02 Dec 19
